EE04962B1 - Kinoliini ühend, seda sisaldav farmatseutiline kompositsioon, ühendi kasutamine ravimina ning meetod ühendi ja kompositsiooni valmistamiseks - Google Patents
Kinoliini ühend, seda sisaldav farmatseutiline kompositsioon, ühendi kasutamine ravimina ning meetod ühendi ja kompositsiooni valmistamiseksInfo
- Publication number
- EE04962B1 EE04962B1 EEP200100318A EEP200100318A EE04962B1 EE 04962 B1 EE04962 B1 EE 04962B1 EE P200100318 A EEP200100318 A EE P200100318A EE P200100318 A EEP200100318 A EE P200100318A EE 04962 B1 EE04962 B1 EE 04962B1
- Authority
- EE
- Estonia
- Prior art keywords
- compound
- medicament
- preparation
- quinoline
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 quinoline compound Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
- Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98204444 | 1998-12-23 | ||
| PCT/EP1999/010214 WO2000039082A2 (en) | 1998-12-23 | 1999-12-17 | 1,2-annelated quinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200100318A EE200100318A (et) | 2002-10-15 |
| EE04962B1 true EE04962B1 (et) | 2008-02-15 |
Family
ID=8234557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200100318A EE04962B1 (et) | 1998-12-23 | 1999-12-17 | Kinoliini ühend, seda sisaldav farmatseutiline kompositsioon, ühendi kasutamine ravimina ning meetod ühendi ja kompositsiooni valmistamiseks |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US6458800B1 (cs) |
| EP (1) | EP1140935B1 (cs) |
| JP (1) | JP4725940B2 (cs) |
| KR (2) | KR100712226B1 (cs) |
| CN (1) | CN1178938C (cs) |
| AR (1) | AR021995A1 (cs) |
| AT (1) | ATE240327T1 (cs) |
| AU (1) | AU765437B2 (cs) |
| BG (1) | BG65124B1 (cs) |
| BR (1) | BR9916827A (cs) |
| CA (1) | CA2355717C (cs) |
| CZ (1) | CZ302374B6 (cs) |
| DE (1) | DE69907964T2 (cs) |
| DK (1) | DK1140935T3 (cs) |
| EA (1) | EA004542B1 (cs) |
| EE (1) | EE04962B1 (cs) |
| ES (1) | ES2200591T3 (cs) |
| HK (1) | HK1038746B (cs) |
| HR (1) | HRP20010454B1 (cs) |
| HU (1) | HU229404B1 (cs) |
| ID (1) | ID29241A (cs) |
| IL (2) | IL143859A0 (cs) |
| NO (1) | NO318922B1 (cs) |
| PL (1) | PL199080B1 (cs) |
| PT (1) | PT1140935E (cs) |
| SI (1) | SI1140935T1 (cs) |
| SK (1) | SK286072B6 (cs) |
| TR (1) | TR200101961T2 (cs) |
| TW (1) | TW531533B (cs) |
| UA (1) | UA71592C2 (cs) |
| WO (1) | WO2000039082A2 (cs) |
| ZA (1) | ZA200105136B (cs) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE323474T1 (de) * | 2000-02-04 | 2006-05-15 | Janssen Pharmaceutica Nv | Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs |
| AU2001231763A1 (en) | 2000-02-24 | 2001-09-03 | Janssen Pharmaceutica N.V. | Dosing regimen |
| JP2003525245A (ja) * | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 |
| CA2397240A1 (en) * | 2000-02-29 | 2001-09-07 | Peter Albert Palmer | Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
| CA2397446A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica Inc. | Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
| US20030022918A1 (en) * | 2000-02-29 | 2003-01-30 | Horak Ivan David | Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| EP1267872A2 (en) * | 2000-02-29 | 2003-01-02 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| US20030027808A1 (en) * | 2000-02-29 | 2003-02-06 | Palmer Peter Albert | Farnesyl protein transferase inhibitor combinations with platinum compounds |
| WO2001064195A2 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| EP1267871A2 (en) * | 2000-02-29 | 2003-01-02 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| CA2397448A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| JP2003525239A (ja) * | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 |
| AU2001242434A1 (en) * | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| JO2361B1 (en) * | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
| ES2261476T3 (es) * | 2000-09-25 | 2006-11-16 | Janssen Pharmaceutica N.V. | Derivados de quinolina y quinazolina que inhiben la farnesil-tranferasa como inhibidores de farnesil-tranferasa. |
| EP1322644A1 (en) | 2000-09-25 | 2003-07-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
| US7173040B2 (en) * | 2000-09-25 | 2007-02-06 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives |
| ES2313991T3 (es) * | 2000-09-25 | 2009-03-16 | Janssen Pharmaceutica Nv | Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa. |
| CZ20031145A3 (cs) * | 2000-10-02 | 2003-12-17 | Janssen Pharmaceutica N.V. | Antagonisté metabotropního glutamátového receptoru |
| ATE434615T1 (de) * | 2000-11-21 | 2009-07-15 | Janssen Pharmaceutica Nv | Farnesyltransferase hemmende benzoheterocyclische derivate |
| JP4231691B2 (ja) * | 2000-11-28 | 2009-03-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 炎症性腸疾患の治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤 |
| ES2260316T3 (es) | 2000-12-27 | 2006-11-01 | Janssen Pharmaceutica N.V. | Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa. |
| ES2318000T3 (es) * | 2001-02-15 | 2009-05-01 | Janssen Pharmaceutica Nv | Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos. |
| WO2002085364A1 (en) * | 2001-04-25 | 2002-10-31 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for treating cachexia |
| US6740757B2 (en) * | 2001-08-29 | 2004-05-25 | Pfizer Inc | Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer |
| WO2003045313A2 (en) * | 2001-11-27 | 2003-06-05 | Merck & Co. Inc. | 2-aminoquinoline compounds |
| JP4537710B2 (ja) | 2001-12-19 | 2010-09-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼ阻害剤としての炭素連結トリアゾールで置換されている１，８−アネル化キノリン誘導体 |
| EP1490065B1 (en) | 2002-03-22 | 2007-06-13 | Janssen Pharmaceutica N.V. | Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors |
| NZ535438A (en) * | 2002-03-29 | 2006-08-31 | Janssen Pharmaceutica Nv | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
| WO2003087101A1 (en) | 2002-04-15 | 2003-10-23 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
| US20030125268A1 (en) * | 2002-08-28 | 2003-07-03 | Rybak Mary Ellen Margaret | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| WO2005030774A1 (en) | 2003-09-26 | 2005-04-07 | Rigel Pharmaceuticals, Inc. | Hcv inhibitors and methods of using them |
| WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
| US20060111398A1 (en) | 2004-11-05 | 2006-05-25 | Fourie Anne M | Therapeutic use of farnesyltransferase inhibitors and methods of monitoring the efficacy thereof |
| US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
| US20060281755A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
| US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| US20060281769A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
| US20070213366A1 (en) | 2005-12-23 | 2007-09-13 | Justman Craig J | Treatment of Synucleinopathies |
| DE102006012545A1 (de) * | 2006-03-18 | 2007-09-27 | Sanofi-Aventis | Substituierte 2-Amino-4-phenyl-dihydrochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| JP5331680B2 (ja) | 2006-04-20 | 2013-10-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ｃ−ｆｍｓキナーゼの阻害剤 |
| US8697716B2 (en) * | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| PT2021335E (pt) | 2006-04-20 | 2011-07-25 | Janssen Pharmaceutica Nv | Compostos heterocíclicos como inibidores de c-fms quinase |
| JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| WO2009151683A2 (en) | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| WO2010057006A1 (en) | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
| TW201329025A (zh) | 2011-11-01 | 2013-07-16 | Astex Therapeutics Ltd | 醫藥化合物 |
| RU2014136226A (ru) * | 2012-02-13 | 2016-04-10 | Ф.Хоффманн-Ля Рош Аг | Производные имидазолилкетона в качестве ингибиторов альдостеронсинтазы |
| JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
| IN2015DN00659A (cs) | 2012-08-07 | 2015-06-26 | Janssen Pharmaceutica Nv | |
| MY189505A (en) | 2012-10-16 | 2022-02-16 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of roryt |
| CN105073729A (zh) | 2012-10-16 | 2015-11-18 | 詹森药业有限公司 | RORγt的苯基连接的喹啉基调节剂 |
| ES2619610T3 (es) | 2012-10-16 | 2017-06-26 | Janssen Pharmaceutica Nv | Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| EP3057421B1 (en) | 2013-10-15 | 2019-11-20 | Janssen Pharmaceutica NV | Alkyl linked quinolinyl modulators of ror(gamma)t |
| KR20160068956A (ko) | 2013-10-15 | 2016-06-15 | 얀센 파마슈티카 엔.브이. | RORyT의 퀴놀리닐 조절제 |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US20180338993A1 (en) * | 2014-12-04 | 2018-11-29 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| KR102514971B1 (ko) | 2015-04-21 | 2023-03-27 | 아이거 바이오파마슈티컬스 인코포레이티드 | 로나파르닙 및 리토나버를 포함하는 약제 조성물 |
| EP3385395B9 (en) | 2015-08-17 | 2020-05-20 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyl transferase inhibitors |
| CN109071425B (zh) * | 2016-03-23 | 2021-01-15 | 陈裕仁 | 法尼基转移酶抑制剂及其用途 |
| US11124839B2 (en) | 2016-11-03 | 2021-09-21 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2002864C (en) | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
| TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| EP0865440B1 (en) * | 1995-12-08 | 2002-04-03 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives |
| TW591030B (en) * | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
| US6177432B1 (en) * | 1997-04-25 | 2001-01-23 | Janssen-Cilag S.A. | Farnesyltransferase inhibiting quinazolinones |
| IL133212A (en) * | 1997-06-02 | 2005-12-18 | Janssen Pharmaceutica Nv | History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells |
-
1999
- 1999-12-17 AU AU27953/00A patent/AU765437B2/en not_active Expired
- 1999-12-17 CN CNB99814763XA patent/CN1178938C/zh not_active Expired - Lifetime
- 1999-12-17 HU HU0104582A patent/HU229404B1/hu unknown
- 1999-12-17 AT AT99969220T patent/ATE240327T1/de active
- 1999-12-17 ES ES99969220T patent/ES2200591T3/es not_active Expired - Lifetime
- 1999-12-17 PT PT99969220T patent/PT1140935E/pt unknown
- 1999-12-17 HR HR20010454A patent/HRP20010454B1/xx not_active IP Right Cessation
- 1999-12-17 WO PCT/EP1999/010214 patent/WO2000039082A2/en not_active Application Discontinuation
- 1999-12-17 DK DK99969220T patent/DK1140935T3/da active
- 1999-12-17 US US09/868,992 patent/US6458800B1/en not_active Expired - Lifetime
- 1999-12-17 KR KR1020017006140A patent/KR100712226B1/ko not_active Expired - Lifetime
- 1999-12-17 UA UA2001064401A patent/UA71592C2/uk unknown
- 1999-12-17 TR TR2001/01961T patent/TR200101961T2/xx unknown
- 1999-12-17 JP JP2000590995A patent/JP4725940B2/ja not_active Expired - Lifetime
- 1999-12-17 EE EEP200100318A patent/EE04962B1/xx unknown
- 1999-12-17 BR BR9916827-8A patent/BR9916827A/pt not_active Application Discontinuation
- 1999-12-17 SI SI9930350T patent/SI1140935T1/xx unknown
- 1999-12-17 ID IDW00200101373A patent/ID29241A/id unknown
- 1999-12-17 CZ CZ20012142A patent/CZ302374B6/cs not_active IP Right Cessation
- 1999-12-17 SK SK873-2001A patent/SK286072B6/sk not_active IP Right Cessation
- 1999-12-17 KR KR1020067021243A patent/KR100818541B1/ko not_active Expired - Lifetime
- 1999-12-17 EA EA200100708A patent/EA004542B1/ru not_active IP Right Cessation
- 1999-12-17 PL PL349504A patent/PL199080B1/pl unknown
- 1999-12-17 EP EP99969220A patent/EP1140935B1/en not_active Expired - Lifetime
- 1999-12-17 IL IL14385999A patent/IL143859A0/xx active IP Right Grant
- 1999-12-17 TW TW088122193A patent/TW531533B/zh not_active IP Right Cessation
- 1999-12-17 DE DE69907964T patent/DE69907964T2/de not_active Expired - Lifetime
- 1999-12-17 HK HK02100160.2A patent/HK1038746B/en not_active IP Right Cessation
- 1999-12-17 CA CA2355717A patent/CA2355717C/en not_active Expired - Lifetime
- 1999-12-22 AR ARP990106687A patent/AR021995A1/es active IP Right Grant
-
2001
- 2001-06-20 IL IL143859A patent/IL143859A/en not_active IP Right Cessation
- 2001-06-20 BG BG105631A patent/BG65124B1/bg unknown
- 2001-06-21 NO NO20013088A patent/NO318922B1/no not_active IP Right Cessation
- 2001-06-21 ZA ZA200105136A patent/ZA200105136B/en unknown
-
2002
- 2002-06-24 US US10/179,444 patent/US6914066B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE04962B1 (et) | Kinoliini ühend, seda sisaldav farmatseutiline kompositsioon, ühendi kasutamine ravimina ning meetod ühendi ja kompositsiooni valmistamiseks | |
| EE200100280A (et) | Kinoliini ja kinoksaliini ühend, seda sisaldav farmatseutiline kompositsioon ning ühendi kasutamine | |
| EE200100278A (et) | Kinoliini ja kinoksaliini ühend, seda sisaldav farmatseutiline kompositsioon ning ühendi kasutamine | |
| EE200100279A (et) | Kinoliini ja kinoksaliini ühend, seda sisaldav farmatseutiline kompositsioon ning ühendi kasutamine | |
| NO20006630L (no) | Farmasöytisk sammensetning for behandlingen av diabetes | |
| HUP0303398A3 (en) | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof and pharmaceutical compositions containing the same | |
| HUP0204226A3 (en) | Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds | |
| EE200000535A (et) | Triasendatud 1,3,5-triasiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ning kombineeritud preparaat kasutami | |
| EE04850B1 (et) | Pürimidiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ning kombineeritud preparaat kasutamiseks HIV nakku | |
| EE04275B1 (et) | Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid | |
| EE200000482A (et) | Glütsiini ülekannet pärssiva ühendi kasutamine ravimi valmistamiseks, ühend, seda sisaldav kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks | |
| EE04464B1 (et) | Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid | |
| EE200100252A (et) | Pürimidiinderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja sellevalmistamismeetod, kombinatsioon ning saadus | |
| EE200000483A (et) | Glütsiini ülekannet pärssiva ühendi kasutamine ravimi valmistamiseks, ühend, seda sisaldav kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks | |
| EE05183B1 (et) | Asabitsklilised hendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon | |
| PL396568A1 (pl) | Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postać dawkowania, doustna postać dawkowania, zastosowanie oraz sposób wytwarzania krystalicznego bursztynianu O-demetylo-wenlafaksyny | |
| HUP0203902A3 (en) | Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use | |
| HUP0203142A3 (en) | Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use | |
| EE200100495A (et) | Sahhariidijääkidega asendatud 1,4-bensotiasepiin-1,1-dioksiidi derivaadid, meetod nende valmistamiseks, ühendite kasutamine ning neid sisaldav ravim | |
| HUP0203183A3 (en) | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use | |
| AU4949800A (en) | 2-arylpurine-9-acetamide derivatives, process for the preparation thereof, medicinal compositions containing the same and intermediates of the derivatives | |
| IL138969A0 (en) | Anthranilic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
| HUP0105313A3 (en) | Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use | |
| HUP0105108A3 (en) | Amide compounds, process for their preparation and pharmaceutical compositions containing them | |
| ZA985392B (en) | New derivatives of 2-(iminomethyl) amino-phenyl, their preparation their use as medicaments and the pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20101231 |